Physician profile
Mui T Ly
NPI 1811133028
$699.49
in general payments reported to CMS, 2019-2025
12 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.81 · 2020: $20.62 · 2021: $73.38 · 2022: $68.20 · 2023: $139 · 2024: $118 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $184.55 | 2020-2025 | Total30, Precision 1, Precision7 |
| Dompe US, INC. | $125.22 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $76.66 | 2023-2025 | Infuse, Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $65.24 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $49.37 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.78 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $37.08 | 2023 | Cequa |
| Johnson & Johnson Vision Care, INC. | $37.00 | 2023 | |
| Astellas Pharma US INC | $23.54 | 2025 | Izervay |
| Allergan, INC. | $21.80 | 2021 | |
| Abbvie INC. | $18.83 | 2022 | |
| Shire North American Group INC | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mui Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.